Immunorizon

Company Overview

Snapshot

Founded in December 2017, Immunorizon operates with 1–10 employees. The company was acquired by Purple Biotech in February 2023, following three funding rounds with M Ventures and ExploreBio as investors.

Business overview

Immunorizon specializes in developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company focuses on extending its pipeline through tri-specific constructs that incorporate additional tumor-associated antigens and diverse engagers targeting both T-cells and NK-cells. Operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development, Immunorizon serves the oncology market with its biotechnology solutions.

Company Intelligence Q&A

What is Immunorizon's primary focus?

Immunorizon is focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.

When was Immunorizon founded?

Immunorizon was founded in December 2017.

What is the status of Immunorizon?

Immunorizon was acquired by Purple Biotech in February 2023.

Which investors participated in Immunorizon's funding rounds?

Immunorizon received funding from M Ventures and ExploreBio in its December 2017 seed round. M Ventures also participated in subsequent seed rounds in April 2019 and February 2020.

What type of products does Immunorizon develop?

Immunorizon develops biotechnology products, specifically antibodies for cancer therapy, which are currently in the clinical trial stage.